A pharmacokinetic study in healthy adults showed that doubling the dose of coformulated lopinavir/ritonavir was able to overcome the inducing effect of rifampicin. We evaluated this strategy in children treated with rifampicinbased antituberculosis therapy attending antiretroviral clinics in South Africa. Treatment options are limited for young children with HIV-associated tuberculosis. Through induction of CYP3A4 and p-glycoprotein expression, rifampicin reduces trough concentrations of lopinavir by >90% in healthy volunteers given standard doses of lopinavir/ritonavir (LPV/r) [1] . We previously demonstrated that acceptable concentrations of lopinavir were achieved in >85% of children during rifampicin-based antituberculosis treatment, when extra ritonavir was added to standard doses of LPV/r ('super-boosted' lopinavir) [2] . However, implementation of superboosted lopinavir is not practical in many settings as it is complex to administer, and ritonavir solution has a short shelf life and is often in short supply. An alternative approach using double doses of LPV/r achieved adequate concentrations of lopinavir in adults given rifampicin concurrently [1, 3] , but this approach has not been evaluated in children. We studied plasma concentrations of lopinavir in South African children treated with twice the standard doses of LPV/r during rifampicin-based antituberculosis therapy, and a group of controls without tuberculosis receiving antiretroviral therapy (ART) which included standard doses of LPV/r.
Background: Coadministration of rifampicin dramatically reduces the concentrations of protease inhibitors.
A pharmacokinetic study in healthy adults showed that doubling the dose of coformulated lopinavir/ritonavir was able to overcome the inducing effect of rifampicin. We evaluated this strategy in children treated with rifampicinbased antituberculosis therapy attending antiretroviral clinics in South Africa. Treatment options are limited for young children with HIV-associated tuberculosis. Through induction of CYP3A4 and p-glycoprotein expression, rifampicin reduces trough concentrations of lopinavir by >90% in healthy volunteers given standard doses of lopinavir/ritonavir (LPV/r) [1] . We previously demonstrated that acceptable concentrations of lopinavir were achieved in >85% of children during rifampicin-based antituberculosis treatment, when extra ritonavir was added to standard doses of LPV/r ('super-boosted' lopinavir) [2] . However, implementation of superboosted lopinavir is not practical in many settings as it is complex to administer, and ritonavir solution has a short shelf life and is often in short supply. An alternative approach using double doses of LPV/r achieved adequate concentrations of lopinavir in adults given rifampicin concurrently [1, 3] , but this approach has not been evaluated in children. We studied plasma concentrations of lopinavir in South African children treated with twice the standard doses of LPV/r during rifampicin-based antituberculosis therapy, and a group of controls without tuberculosis receiving antiretroviral therapy (ART) which included standard doses of LPV/r. 
Short communication

Introduction
Methods
Children >6 months old who were eligible to receive ART comprising LPV/r and dual nucleoside reverse transcriptase inhibitors (NRTIs), which is the firstline ART regimen for children in South Africa, were recruited at three paediatric HIV clinics. A parent or legal guardian provided written informed consent to participate in the study, and children older than 7 years gave their assent. The research ethics committees of Cape Town, Stellenbosch and Witwatersrand Universities approved the study. Children with tuberculosis were treated with antituberculosis regimens containing daily 10 mg/kg doses of rifampicin in accordance with the National Tuberculosis Control Programme. ART was started after antituberculosis therapy and the doses of LPV/r were doubled (460/115 mg/m 2 twice daily). The plasma pharmacokinetics of lopinavir were measured after at least 2 weeks of combined antituberculosis and ART. Children without tuberculosis underwent pharmacokinetic evaluation after at least 2 weeks on ART with standard doses of LPV/r (230/57.5 mg/m 2 twice daily). LPV/r was administered as Kaletra ® oral solution and the doses calculated according to body surface area were rounded up to the nearest 0.1 ml. Blood samples were drawn just prior to, and at 2, 4 and 8 h after an observed dose of LPV/r. In a subgroup, 12 h samples were drawn. Pre-dose lopinavir concentrations were available within 2 weeks of sampling to allow dose adjustment at the discretion of the attending clinician.
During antituberculosis therapy, alanine transaminase (ALT) was monitored at baseline prior to starting ART, after 2 and 4 weeks of cotreatment and then monthly. Random (non-fasting) serum triglyceride, cholesterol and glucose were measured prior to starting ART, and at 1, 6 and 12 months.
Plasma concentrations of lopinavir were determined by a validated liquid chromatography-tandem mass spectrometry method described previously [2] . The calibration curve was linear over the range 0.05-20 mg/l. Any sample whose lopinavir results were determined to be above 20 mg/l was diluted with drug-free plasma and reanalysed. Accuracy ranged from 94.0% to 105.0%. The intra-day and interday precisions ranged from 0.2% to 5.1% and from 1.8% to 5.3%, respectively. Lopinavir concentrations >20% below the limit of quantification (0.05 mg/l) were given a value of 0.02 mg/l. Peak concentration was determined directly from the concentration-time data and the area under the curve until the 8 h time point was calculated using the linear trapezoidal rule. Z-scores were calculated using Epi Info2000 (CDC, Atlanta, GA, USA). The Wilcoxon rank-sum (independent groups), Wilcoxon signed-rank (paired data) and Fisher's exact (binomial data) tests were used to evaluate the differences between two groups. Spearman rank correlation coefficient described associations between continuous variables. Stata version 11.0 (StataCorp, College Station, TX, USA) was used to compute the pharmacokinetic measures, summary statistics and statistical tests.
Results
A total of 17 children with tuberculosis and 24 controls underwent pharmacokinetic sampling. The data safety and monitoring board recommended stopping enrolment after review of the interim pharmacokinetic results, which showed that lopinavir concentrations were suboptimal. As ongoing therapeutic drug monitoring of lopinavir trough concentrations was offered to participating children until all children had completed antituberculosis treatment, an additional 3 children with tuberculosis had pre-dose lopinavir concentrations measured whilst receiving 'double-dose' LPV/r.
Patient characteristics at the time of pharmacokinetic sampling and pharmacokinetic measures are summarized in Table 1 . Four lopinavir concentrations were <0.05 mg/l. Lopinavir pre-dose concentrations varied considerably (range <0.05-11.1 mg/l during antituberculosis treatment; 0.2-24.5 mg/l in controls). Pre-dose lopinavir concentrations were <1 mg/l (the lower limit of the recommended range [4] ) in 60% (12/20) of children with tuberculosis, compared with 2 of 24 (8%) controls (P<0.001).
Amongst children receiving antituberculosis therapy, pre-dose lopinavir concentrations were correlated with weight for height z-score (Figure 1 ), but not with height for age z-score, weight, age, sex, lopinavir dose/ unit body surface area or duration of ART.
ALT elevations >5× the upper normal limit were detected in two children with tuberculosis: one child was diagnosed with acute hepatitis A virus infection; the other had two episodes of transaminitis. Neither child developed clinical signs of hepatitis, and ALT returned to the normal range without treatment interruption. No grade 3 or 4 (based on Division of AIDS table for grading the severity of adult and paediatric adverse events, version 1) elevations of cholesterol, triglycerides or glucose were recorded.
A total of 18 children with tuberculosis had viral load results at the 5-or 6-month visit after starting ART. Lopinavir pre-dose concentrations were not different in the 9 children with viral loads >400 copies/ ml and the 9 children with viral loads <400 copies/ml 
Discussion
Our finding that doubling the doses of LPV/r in children on concomitant antituberculosis therapy failed to achieve adequate lopinavir concentrations was unanticipated as this approach has been successful in adults. This observation underlines the need for pharmacokinetic studies in children to support dosing approaches. Although young children often have higher apparent clearance of drugs and altered absorption compared to older children and adults, the dramatic reduction in lopinavir concentrations in children with tuberculosis compared to controls of a similar age requires additional explanation. Differences in the magnitude and duration of drug interactions involving induction or inhibition of metabolizing enzymes and transporters between adults and children are not well-understood. Whether the bioavailability of the oral solution of LPV/r may be more affected by intestinal induction of p-glycoprotein and CYP 3A4 than the solid formulations is also unknown. Poor adherence to treatment is an unlikely explanation for the low lopinavir concentrations as lopinavir concentrations 12 h after the observed dose tended to be lower than pre-dose concentrations (median 0.3 versus 1.3 mg/l; P=0.46) in the sub-group of six children with tuberculosis who underwent sampling at 12 h, suggesting that the evening dose was taken prior to pharmacokinetic evaluation. Furthermore, full adherence to their antiretroviral treatment during the 3 days before pharmacokinetic evaluation was reported for 19 of 20 children with tuberculosis by the accompanying adult and treatment doses were observed in the clinics on the day of sampling. The strong association between weight for height z-scores and pre-dose lopinavir concentrations suggests that wasting is an important risk factor for underexposure to lopinavir in children with tuberculosis. The lack of an association between age and predose concentrations of lopinavir might be due to the relatively small number of children in our study across a limited age range. As they were not represented in our study population, our findings should not be applied to older children. In contrast to findings amongst healthy adult volunteers pre-induced with rifampicin before the Table 1 . Patient characteristics and pharmacokinetic measures in children with HIV-associated tuberculosis and controls without tuberculosis.
Data are medians (IQR) unless otherwise indicated. a n=17. ART, antiretroviral therapy; AUC 0-8 , area under the curve until the 8 h time point; BMI, body mass index; BSA, body surface area; C max , peak concentration; NS, not significant; PK, pharmacokinetic; TB, tuberculosis.
Weight for height z-score addition of increased doses of LPV/r [5] , only one (5%) child developed hepatotoxicity likely due to the treatment combination. A key question is whether the low lopinavir concentrations in children with tuberculosis taking doubledose LPV/r would result in poorer outcomes. Our study lacked the power to answer this question and interpretation of the relationship between pharmacokinetics and viral response is further complicated by adjustments to the doses of their lopinavir and ritonavir in some children after pharmacokinetic evaluation. However, results from a recently reported South African study provide compelling evidence that our pharmacokinetic findings would influence outcomes. This retrospective record review evaluated 6-month virological outcomes in three groups of children whose ART regimens included LPV/r: controls without tuberculosis on standard doses of LPV/r, and children with tuberculosis receiving either double-dose LPV/r or super-boosted lopinavir [6] . The proportion of children achieving viral suppression compared with controls was lower in children with tuberculosis on double-dose LPV/r, but similar in children with tuberculosis on super-boosted lopinavir regimens, which we have previously shown to result in adequate lopinavir trough concentrations in most children.
For children younger than 3 years on rifampicincontaining antituberculosis treatment the World Health Organization recommends two ART regimens: triple NRTIs or nevirapine plus two NRTIs [7] . Neither of these approaches has been adequately evaluated in children with tuberculosis. Triple NRTI regimens are associated with high rates of NRTI mutations and virological failure in children without tuberculosis [8, 9] . Rifampicin induces glucuronidation of abacavir and zidovudine, which may further increase the risks of virological failure of triple NRTI regimens if either of these NRTIs are used. Nevirapine pre-dose concentrations below the recommended range were found in 52% of children (median age 1.5 years) with tuberculosis and their median pre-dose concentration was half that of controls without tuberculosis [10] , suggesting that virological efficacy is likely to be compromised. There are currently no dosing recommendations for efavirenz in children younger than 3 years. In many countries, policies to prevent vertical transmission of HIV from mother to child rely on the use of preventive regimens including single-dose nevirapine or maternal ART including a non-nucleoside reverse transcriptase inhibitor (NNRTI). Due to the risk of NNRTIresistance mutations in infants with prior exposure to NNRTIs, LPV/r plus two NRTIs is the preferred antiretroviral regimen [7] . While the risk of tuberculosis is diminished in patients established on effective ART, patients in high burden settings have an ongoing risk of developing tuberculosis, which is higher than that of the HIV-uninfected population [11] . In low-and middle-income countries, children who fail first-line regimens including NNRTIs only have protease-inhibitor-based second-line regimes available. An alternative approach to adjusting the dose of protease inhibitors in patients on antituberculosis treatment is to replace rifampicin with rifabutin, which has little effect on protease inhibitor concentrations. However, rifabutin is not suitably formulated for children and data to guide dosing are lacking. Although acceptable concentrations of lopinavir were achieved during rifampicinbased antituberculosis treatment when super-boosted lopinavir was used, this approach is difficult to adopt in operational settings because it is complex to prescribe and administer, ritonavir oral solution has a short shelf-life and requires refrigeration, and stockouts of ritonavir solution are more likely as it will only be used for super-boosting. In this study we demonstrated that the alternative approach of using double doses of coformulated LPV/r every 12 h should not be used in young children because trough concentrations of lopinavir were below the minimum recommended concentration in the majority of children. It may be appropriate to use increased doses of LPV/r more frequently, for example, every 8 h, and this approach deserves investigation. There is an urgent need for safe and effective alternatives to nevirapine-based ART that can be used with antituberculosis therapy in young children and that are formulated in a manner not requiring refrigeration.
